Despina Siolas, Assistant Professor at Weill Cornell Medicine shared a post on LinkedIn:
“Rethinking KRAS in pancreatic cancer
Had the privilege of speaking at the 2nd Annual NYC Pancreas Cancer Consortium on the clinical differences among KRAS mutant tumors in pancreatic cancer. Defining mutation-specific effects will be an important endeavor for developing more precise, biology-driven therapies.
Grateful to share our lab’s work alongside colleagues across NYC committed to advancing pancreatic cancer care.”
Other articles featuring Despina Siolas.